Compare EBF & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | CABA |
|---|---|---|
| Founded | 1909 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 495.7M |
| IPO Year | 1994 | 2019 |
| Metric | EBF | CABA |
|---|---|---|
| Price | $21.49 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 160.1K | ★ 5.6M |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | 7.79 | ★ 10.26 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.30 | $1.26 |
| 52 Week High | $22.36 | $4.23 |
| Indicator | EBF | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 51.38 |
| Support Level | $19.92 | $3.12 |
| Resistance Level | $22.36 | $3.34 |
| Average True Range (ATR) | 0.58 | 0.21 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 77.72 | 82.35 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.